Seres Therapeutics (MCRB) Misses Q2 EPS by 218c
Tweet
Share
E-mailGet Alerts MCRB Hot Sheet
Join SI Premium – FREE
Seres Therapeutics (NASDAQ: MCRB) reported Q2 EPS of ($2.27), $2.18 worse than the analyst estimate of ($0.09).
For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fed’s Waller open to September rate hold - if disinflation holds up
- Duluth Holdings Inc. (DLTH) Tops Q2 EPS by 49c
- BRP Inc. (DOO) Reports Q2 Loss of Cd$0.18
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
